{"filing":{"accession_number":"0001438533-26-000062","cik":"0001438533","ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-04","primary_document":"tvtx-20260804.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853326000062/tvtx-20260804.htm"},"events":[{"id":23964,"run_id":21676,"accession_number":"0001438533-26-000062","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing Travere Therapeutics' second quarter 2026 financial results. The filing explicitly states \"Travere Therapeutics Reports Second Quarter 2026 Financial Results\" and discloses key metrics including U.S. net product sales of $161.4 million (up from $94.8 million YoY), FILSPARI sales of $141.1 million (96% YoY growth), R\u0026D and SG\u0026A expenses, and net loss of $34.8 million. The press release is attached as Exhibit 99.1 and covers both financial results and material corporate updates including FDA approval of FILSPARI for FSGS and the in-licensing of civorebrutinib.","company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24331,"accession_number":"0001438533-26-000062","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Travere Therapeutics' second quarter 2026 financial results. The filing explicitly states \"Travere Therapeutics Reports Second Quarter 2026 Financial Results\" and discloses key metrics including U.S. net product sales of $161.4 million (up from $94.8 million YoY), FILSPARI sales of $141.1 million (96% YoY growth), R\u0026D and SG\u0026A expenses, and net loss of $34.8 million. The press release is attached as Exhibit 99.1 and covers both financial results and material corporate updates including FDA approval of FILSPARI for FSGS and the in-licensing of civorebrutinib.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:34:25.333860+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24331,"accession_number":"0001438533-26-000062","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Travere Therapeutics' second quarter 2026 financial results. The filing explicitly states \"Travere Therapeutics Reports Second Quarter 2026 Financial Results\" and discloses key metrics including U.S. net product sales of $161.4 million (up from $94.8 million YoY), FILSPARI sales of $141.1 million (96% YoY growth), R\u0026D and SG\u0026A expenses, and net loss of $34.8 million. The press release is attached as Exhibit 99.1 and covers both financial results and material corporate updates including FDA approval of FILSPARI for FSGS and the in-licensing of civorebrutinib.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:34:25.333860+00:00","company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","filing_date":"2026-08-04"}]}